DNTH Company Profile and Key Details

DNTH has shown sold momentum, gaining 3.89% over the past week and 15.92% over the past quarter, though year-to-date performance is up 100.78%. Short-term trend indicators are bearishly aligned (SMA20 1.62%, SMA50 12.47%, SMA200 63.38%). The stock’s 14-day RSI is 61.52 (firm momentum), while the ATR of 2.0 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -3.71% below its high and over 227.5% above its low. Average 10-day trading volume of 1.22 million shares is significantly above the 3-month average of 671.76 thousand, indicating heightened recent market interest.

Dianthus Therapeutics, Inc. generated EPS of -$3.49 over the past year. Five-year average earnings growth is 40.14%. Wall Street analysts project EPS growth of -17.45% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 8 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $100.00 to $36.00. The high target offers 128.47% upside. The low target suggests -17.75% downside. The mean target is $58.40. This offers 33.42% upside. Dianthus Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 12.79%. The prior quarter beat by 2.33%. Over the last six quarters, Apple has recorded several small beats. These include 2.0% in August 08, 2024.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) closed at $42.61 USD, losing -$1.16 (-2.65%) from the previous close of $43.77. The stock is currently mid-range between its 52-week high and low $13.37 and $45.46. With a market capitalization of about $1.54 billion, Dianthus Therapeutics, Inc. is classified as a small-cap and shows market-like volatility (beta ~1.19). Key stats such as the average daily volume over the past year has been around 682.83 thousand shares, in line with its 52-week average. Headquartered in New York City, NY, Dianthus Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Marino Garcia, the company employs approximately 78 people and listed since June 21, 2018. Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases.

Dianthus Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$6.95. This means the shares are trading below this model’s fair value.

Dianthus Therapeutics, Inc. has 39.82 million shares outstanding. The public float is 11.34 million shares, elevated short interest at 21.21% of float. This equals 5.58 million shares. The short ratio is 15.25 days. Institutional investors hold 133.49% of the float. Insiders own 7.86%. Fairmount Funds Management LLC holds 1.93 million shares, Randhawa Simrat has 4.00 thousand shares and Savitz Ryan has 0.00 shares. Over the past six months, insider transactions show net selling. They sold 167.61 thousand shares across 4 transactions.

Our AI price prediction model suggests that Dianthus Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.48%, with price expected at $41.81 by January 05, 2026, within a range of $40.42 to $43.34 3-Month Outlook: Projected rise of 38.91%, reaching $60.80 by March 20, 2026, with a range of $59.81 to $62.14. 1-Year Outlook: Projected gain of 22.48%, with price at $53.61 by December 22, 2026, within a range of $51.18 to $55.76.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares are up 100.78% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Dianthus Therapeutics, Inc. trading at a premium to the broader market with a P/E of -12.7. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $56.78, suggesting 29.72% upside. Our AI forecast model points to short-term weakness (-4.48% over two weeks), a medium-term rise (38.91% over three months), and a longer-term gain (22.48% over one year), with expected trading ranges indicating moderate volatility.

Dianthus Therapeutics, Inc. trades at a P/E ratio of -12.7, slightly below the S&P 500 average, with a price-to-sales ratio of 499.29 and a price-to-book ratio of 2.94 suggesting the stock is closer to book value. The P/FCF stands at -14.02, also above market averages.